Adding C15:0 to the short list of Essential Fatty Acids is a very big deal.
I’ve been taking C15:0 for a while. The study takes a bit of reading but I find it compelling.
I’ve inserted a few excerpts for the"time poor" but reading the whole paper is fascinating and well worth the effort. The tables showing the BioMAP test results are compelling.
C15:0 compounds:
To evaluate the repeatability and consistency of human cell phenotypic profiling with C15:0, two C15:0 compounds manufactured at different facilities, Seraphina Therapeutics (FA15TM, pentadecanoic acid 99%) and Millipore Sigma (Sigma-Aldrich Product W433400, pentadecanoic acid 99%), were compared using the BioMAP Diversity Plus Panel (Eurofins DiscoverX, Fremont, California USA).
The reference link to Fatty15 is already in this thread.
The tests included a well regarded EPA supplement.
There are excellent tables showing the comparisons. Spoiler alert, both C15:0 sources were very similar and in many cases, better than EPA.
Here’s a link to the Millipore Sigma product. It costs $340 for 100g.
BioMAP® Diversity PLUS panel is the platform for testing
The BioMAP® Diversity PLUS panel (Eurofins) uses 12 human primary cell-based systems designed to model complex human tissue and disease biology of the vasculature, skin, lung, and inflammatory tissues. Quantitative measurements of 148 clinically relevant biomarker activities across this broad panel, along with comparative analysis of the biological activities of known bioactive agents in the BioMAP reference database, are used to predict the safety, efficacy and function of test agents. The reference database includes BioMAP profiles of over 4,500 compounds with known safety, efficacy and function.
Discussion
First paragraph only. The whole discussion is worth reading as it describes many of the potential beneficial findings of the study.
C15:0 is emerging as an essential fatty acid with pleiotropic and clinically relevant benefits that may help to stem chronic cardiometabolic, liver, and inflammatory diseases. Here, our study demonstrated broad and dose-dependent anti-inflammatory, immunomodulatory and antifibrotic activities of C15:0, including dose dependent activities involving 36 key biomarkers across 10 different human cell systems mimicking various disease states. Overall, these clinically relevant activities were repeated when evaluating two pure C15:0 compounds from different manufacturers.
Conclusion
Demonstrated broad and beneficial activities of C15:0, including many that were improved upon a leading omega-3, support C15:0’s role as an emerging essential fatty acid relevant to both physical and mental health. This study built on the existing literature of C15:0’s anti-cancer and antimicrobial properties, as well as being the first to demonstrate the potential for C15:0 to help manage depression and autoimmune diseases. Given the growing and repeated evidence of C15:0 as a beneficial odd-chain saturated fatty acid, there is a need to reevaluate current nutritional guidelines that continue to recommend lowered intake of all dietary saturated fats.
@Krister_Kauppi @RapAdmin I think C15:0 is a great candidate to be added near the top of the ITP list and should hopefully figure in your own testing plans and perhaps your personal regimes.